AbbVie Inc. is 245.8x more valuable than Viridian Therapeutics, Inc.DE by market capitalization ($399.47 B vs $1.63 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | VRDN | ABBV |
|---|---|---|
| Market cap | $1.63 B | $399.47 B |
| US-listed rank | #2249 | #28 |
| Revenue (latest FY) | $4.00M | $61.16B |
| Net income (latest FY) | -$342.60M | $4.23B |
| Net margin | -8558.6% | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 794 | 1,008 |
AbbVie Inc. is 245.8x more valuable than Viridian Therapeutics, Inc.DE by market capitalization ($399.47 B vs $1.63 B).
In their latest fiscal years, Viridian Therapeutics, Inc.DE reported $4.00M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Viridian Therapeutics, Inc.DE and AbbVie Inc., or browse the full rankings.